Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
6.570
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Revance Therapeutics
< Previous
1
2
3
4
5
6
Next >
45 Biggest Movers From Yesterday
October 13, 2021
Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on...
Via
Benzinga
How Bad Are Revance Therapeutics's Earnings? | Return On Capital Employed
September 03, 2021
Revance Therapeutics (NASDAQ:RVNC) brought in sales totaling $18.80 million during Q2 according to data provided by Benzinga Pro.However, earnings decreased 0.46%, resulting in a...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the...
Via
Talk Markets
Earnings Scheduled For May 10, 2021
May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...
Via
Benzinga
Looking Into Revance Therapeutics's Return On Capital Employed
June 24, 2021
Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. Revance...
Via
Benzinga
Looking Into Revance Therapeutics's Return On Capital Employed
June 08, 2021
Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. In Q4, Revance...
Via
Benzinga
Recap: Revance Therapeutics Q1 Earnings
May 10, 2021
Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the...
Via
Benzinga
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
May 01, 2021
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million...
Via
Talk Markets
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.